Collaborating Organizations

We are thankful to the following organizations for their support and are happy to be working alongside them to support neuroscience research in Canada.

Alzheimer’s Association

The mission of the Alzheimer’s Association is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.

Alzheimer’s Drug Discovery Foundation-Canada

The mission of the Alzheimer’s Drug Discovery Foundation (ADDF) is to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging. Launched in 2013, the Alzheimer’s Drug Discovery Foundation of Canada (ADDF-Canada) is the first international affiliate of the US-based ADDF. ADDF-Canada is focused on expanding preclinical drug discovery and clinical trial capacity in Canada.

Alzheimer’s Research UK (ARUK)

ARUK  is the UK’s leading research charity aiming to defeat dementia, which aims to provide world class studies that give us the best chance of beating dementia sooner.

ARUK’s  pioneering work focuses on prevention, treatment and cure. They energize movements across society to support, fund and take part in dementia research and aim to empower people across all generations through greater understanding of dementia.

Brain Canada

Brain Canada is a national, charitable organization with the vision to understand the brain, in health and illness, to improve lives and achieve societal impact. Brain Canada is achieving its vision by:

  • Increasing the scale and scope of funding to accelerate the pace of Canadian brain research;
  • Creating a collective commitment to brain research across the public, private and voluntary sectors;
  • Delivering transformative, original and outstanding research programs.

The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today.